Status:
RECRUITING
Comparison of Efficacy in SBRT of Large HCC With or Without TACE
Lead Sponsor:
Beijing 302 Hospital
Conditions:
Large HCC Patients
Stereotactic Body Radiation Therapy
Eligibility:
All Genders
30-80 years
Brief Summary
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial ...
Eligibility Criteria
Inclusion
- primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
- single lesion and longest tumor diameter were 5-10cm;
- CP-A or B classification;
- Eastern Cooperative Oncology Group (ECOG) score 0-1;
- distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm
- unsuitable for other therapies, such as patients with heart disease, uncontrolled diabetes, uncontrolled hypertension, etc.
- rejecting other therapies such as resection, liver transplantation, etc.
- platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
- patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.
Exclusion
- tumor thrombus;
- lymph node involvement;
- extrahepatic metastasis.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04512846
Start Date
August 1 2020
End Date
August 30 2026
Last Update
June 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing 302 hospital
Beijing, China, 100039